Reaction
Injection Site Exfoliation reporting signals
As of the last recalculation, Injection Site Exfoliation appears in 653 FAERS reports alongside 7 co-occurring drug terms. The strongest observed disproportionality signal is SARILUMAB (PRR 28.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Sarilumab | 23 | 28.7 | 28.8 |
| Dupilumab | 261 | 28.1 | 28.1 |
| Alirocumab | 12 | 15.5 | 15.5 |
| Interferon Beta-1B | 8 | 13.5 | 13.5 |
| Belimumab | 13 | 13.3 | 13.3 |
| Peginterferon Beta-1A | 5 | 12.2 | 12.2 |
| Inclisiran | 3 | 12.0 | 12.0 |